Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...

On March 5, 2025, the U.S. District Court for the Northern District of Texas denied the Outsourcing Facilities Association’s motion for a ...

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...

Compounding pharmacies faced a major setback in their case over the FDA’s decision to remove the obesity drug tirzepatide ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Adults with type 1 diabetes had greater declines in HbA1c and body weight 1 year after being prescribed semaglutide or tirzepatide. Randomized controlled trials are needed to assess efficacy and ...

Tirzepatide was previously shown to provide sustained weight reductions in adults with obesity. New longer-term findings in adults with both obesity and prediabetes are summarized in a short video.